Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937766 · ClinicalTrials.gov registry record · Phase 3
Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT02937766: Clinical Trial Phase 3 study, sponsored by AMAG Pharmaceuticals.
NCT02937766 is a Phase 3 study that was terminated before completion, run by AMAG Pharmaceuticals. The registered enrollment target is 60 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02937766, a Phase 3 study, was terminated before completion, sponsored by AMAG Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
To demonstrate that Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered subcutaneously via auto-injector is associated with less pain as compared to intramuscular injections of Makena®
Primary Outcome
Comparison of average pain intensity associated with the administration of Makena® via subcutaneous autoinjector versus intramuscular injection (averaged over 4 visits). Score on a scale: 0 (No Pain) up to 10 (Worst Pain Imaginable)
Interventions
- DRUG Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-10-07 |
| Est. Completion | 2017-03-27 |
| Phase | Phase 3 |
Why NCT02937766 stopped before completion
NCT02937766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is the first listed.
NCT02937766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02937766 about?
NCT02937766 is a clinical study titled "Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women". To demonstrate that Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered subcutaneously via auto-injector is associated with less pain as compared to intramuscular injections of Makena®
What is the current status of trial NCT02937766?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2016-10-07. Estimated completion is 2017-03-27.
What interventions are being tested in trial NCT02937766?
The interventions under investigation include: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) (DRUG).
Who is sponsoring clinical trial NCT02937766?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02937766's enrollment target sits among peer trials
60 1804th of 2000 higher than 177 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI